Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Carcinoma, Non-Small-Cell Lung 2Sezary Syndrome 1Sarcoma, Kaposi 1Recurrence 1Lymphoma 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Brentuximab Vedotin 2Bexarotene 2iratumumab 1Vitamin B 12 1Methotrexate 1Folic Acid 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Primary Cutaneous Anaplastic Large Cell × Bexarotene × Clear all
NCT01578499 2021-01-05

ALCANZA

Takeda

Phase 3 Completed
131 enrolled 24 charts
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT01134341 2019-12-18

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
34 enrolled
DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡